Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Monopar Therapeutics Inc. is a clinical-stage biopharma company developing treatments for Wilson disease and radiopharmaceuticals for oncology. Its pipeline includes ALXN1840, an investigational oral drug for Wilson disease, and targeted radiopharmaceuticals like MNPR-101 for cancer imaging and therapy. The company leverages licensing, in-house research, and collaborations to advance precision medicines targeting tumors and rare genetic disorders globally.
This description was generated via AI from an annual report. Updated about 1 year ago.